1. BRUKINSA shows high response rates in CLL patients in SEQUOIA study. 2. Five-year follow-up indicates prolonged OS and PFS with monotherapy for difficult cases. 3. ONC will present new data from SEQUOIA's arms C and D today.
The positive results from the SEQUOIA study could increase investor confidence, similar to past oncology drug approvals that significantly boosted stock prices. Strong clinical data often leads to higher valuations in biotech firms, possibly leading to increased investment interest in ONC.
The article discusses significant clinical trial data directly associated with ONC's product, which can impact market perceptions and investment strategy. Promising clinical results can also create a favorable environment for future fundraising and partnerships.
The stock may react quickly to the presentation of these data, as markets often respond swiftly to clinical trial results. Historically, such announcements can lead to immediate price fluctuations within days to weeks.
SAN CARLOS, California--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), società globale attiva in ambito oncologico, presenterà oggi nuovi dati delle coorti del braccio C e D dello studio clinico fondamentale di fase 3 su scala globale SEQUOIA di BRUKINSA® (zanubrutinib).
Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.